Dandi Fertility

There is a strange gap in the multibillion-dollar fertility industry, and Dandi Fertility found it by reading the fine print. The drugs are engineered. The clinics are gleaming. The diagnostics are venture-funded. And then, at the end of all that sophistication, a patient is handed a syringe, sent home, and told to inject herself with hormones every night for weeks - alone, in a bathroom, hoping she got the angle right.

Dandi's founders looked at that arrangement and asked the question that tends to precede a company: why is the hardest part of fertility care the part nobody bothered to design? Their research put a number on it. In their patient studies, 86% of people named injections as their single biggest pain point. Separately, they found that roughly 70% of clinics list after-hours calls as a major operational headache - and more than 90% of those calls are about, yes, injections.

That is not a marketing problem to be soothed with softer copy. It is a product specification. So in 2021, registered nurse Leyla Bilali - who had spent a decade watching patients panic over their evening shots - teamed up with CEO Jake Kent and co-founder Marni Katz Zimmerman to build for the moment people dread most.

The result is a company that behaves like two companies stapled together, in a good way. One half is a consumer-products business selling a physical kit. The other half is a telehealth service putting a registered fertility nurse on a video call at exactly the moment a patient's hands start to shake. Both halves address the same overlooked minute of the fertility journey: the one where the professional support has gone home and the patient is on her own.

It is a narrow bet, and that is rather the point. In a hot market, the crowded lanes are the obvious ones - the clinics, the drugs, the egg-freezing plans. The opportunity, more often, is in the part of the journey no incumbent wants to own. Dandi decided to own the needle.

The company is named, sincerely, after a dandelion: a small bud that becomes a golden flower, then a white puff whose seeds scatter on the wind to make new life. It reads as branding whimsy until you are the person mid-treatment, and the name quietly reframes waiting as growth. Naming, it turns out, can be a feature too.

Here is the twist that most direct-to-consumer health brands miss. Dandi sells to patients, yes - but roughly 60% of its revenue comes from fertility clinics buying the kits for their own patients. The happiest customer, it turns out, is not always the end user. Sometimes it is the professional who is tired of fielding panic calls at 2am.

That makes Dandi a hybrid: D2C and B2B2C at the same time. A patient can buy the Care Kit directly, or receive it because her clinic decided that a calmer, better-supported patient is a cheaper patient to serve. Both roads lead to the same overlooked minute, and Dandi collects at both ends.

The R&D behind the product earned the endorsements rather than the other way around. Over two years, Dandi worked with more than 100 fertility patients and doctors from leading clinics including Weill Cornell and CCRM. Only after the product was real did the recognition arrive: a TIME Best Invention, a Dezeen Awards longlist, Innovation by Design honors, and public raves from figures like reality-TV star Whitney Port. Olympic gold-medal figure skater Tara Lipinski, herself a fertility patient advocate, joined as Head of Community.

The funding matched the philosophy. Dandi raised $1.3M - not a moonshot valuation, but a tightly scoped bet on a real, felt pain, in a market where you can point to exactly whose evening you made less awful. Canada is flagged as the next market, with employer partnerships and expanded insurance coverage on the roadmap.